Saturday December 15, 2018

New test may prevent antibiotic resistances from spreading

Thereby, physicians would hold a powerful tool from which they could benefit in personalised therapy -- this means the administration of a fitting drug, the researchers said

0
//
Overuse of Antibiotic pills has resulted in development of drug resilient bacterias,, Pixabay
Republish
Reprint
  • Scientists have found a new kind of test
  • This may prevent antibiotic resistance
  • The new method also provides faster diagnosis

Scientists have developed a new “rapid test” that produces a cheaper and faster diagnosis of infectious diseases in just three hours thus preventing antibiotic resistance from spreading.

Owing to small number of pathogens in a patient’s sample, standard practices require up to 72 hours to allow for a reliable result for the infectious diagnostics. The new method provides much faster diagnosis with the help of tiny electrodes that are fixed on the surface of a stamp-sized chip.

Drug overdose
This new test will stop antibiotic resistance. Pixabay

“Electric fields secure bacteria in a very small area,” said Ute Neugebauer from the Friedrich Schiller University Jena in Germany. The scientists then apply various antibiotics in different concentrations on the trapped bacteria and examine them with Raman spectroscopy.

“This means that we irradiate the pathogens with laser light and evaluate the scattered light spectrum”, Neugebauer said. “We combine light-based analytical methods with microfluidic sample processing. With our Lab-on-a-Chip system, thus a miniaturised lab, we are able to clearly identify bacterial strains and their resistances, in less than three hours,” he explained.

Also Read: Asthma Afflicted Children Are Prescribed Unwanted Antibiotics: Study

The combination of fast, light-based diagnostics and a high automation level reduces the time from sampling to result from to date 72 to three and a half hours.

The doctors can then derive whether the strain is resistant or sensible. At the same time they can also derive information on the needed concentration of the antibiotic to constrain bacterial growth.

The test will also lead to faster diagnosis. Wikimedia Commons
The test will also lead to faster diagnosis. Wikimedia Commons

“This is an important diagnostic parameter that influences the success of a treatment decidedly…such a fast procedure could revolutionise diagnostics of infectious diseases”, the researchers said, in a paper published in the journal Analytical Chemistry.

Another, more far-reaching, the aim is the further development of a cartridge-based rapid test system, which will enable general practitioners to identify resistances in a fast and easy way for the first time. Thereby, physicians would hold a powerful tool from which they could benefit in personalised therapy — this means the administration of a fitting drug, the researchers said. IANS

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

New Drug Offers Treatment For Diabetes-Related Blindness

The researchers now plan to conduct a full-scale clinical trial, Gamble said

0
new policy will see the launch of 12 programmes relevant to private schools across the emirate
New drug offers hope for diabetes-related blindness.

In a major breakthrough, Australian scientists have developed a new drug that offers treatment for people suffering from diabetic retinopathy — the main cause of blindness from diabetes.

The debilitating disease occurs when tiny blood vessels in the retina, responsible for detecting light, leak fluid or haemorrhage.

While treatment options include laser surgery or eye injections of anti-vascular endothelial growth factor (VEGF), they are not always effective or can result in side effects, highlighting the need for alternative therapeutic approaches.

The team from the Centenary Institute in Sydney developed a novel drug CD5-2, which in mouse models was found to mend the damaged blood retinal barrier and reduce vascular leakage.

“We believe CD5-2 could potentially be used as a stand-alone therapy to treat those patients who fail to respond to the anti-VEGF treatment. It may also work in conjunction with existing anti-VEGF treatments to extend the effectiveness of the treatment,” said lead author Ka Ka Ting from the Institute.

“With limited treatment options currently available, it is critical we develop alternative strategies for the treatment of this outcome of diabetes,” Ting added.

Diabetes
Representational image. Pixabay

The key process involved in diabetic retinopathy pathology is the breakdown of the blood-retinal barrier (BRB), which is normally impermeable. Its integrity relies on how well capillary endothelial cells are bound together by tight junctions. If the junctions are loose or damaged, the blood vessels can leak.

In the study, reported in the journal Diabetologia, CD5-2 was found to have therapeutic potential for individuals with vascular-leak-associated retinal diseases based on its ease of delivery and its ability to reverse vascular dysfunction as well as inflammatory aspects in animal models of retinopathy.

Previous studies have shown that CD5-2 can have positive effects on the growth of blood vessels.

Also Read- Facebook Invests $1 mn To Boost Computer Science Education

“This drug has shown great promise for the treatment of several major health problems, in the eye and in the brain,” said Professor Jenny Gamble, head of Centenary’s Vascular Biology Programme.

The researchers now plan to conduct a full-scale clinical trial, Gamble said. (IANS)